Founded in 2009, Shenzhen JYMed Technology has spent 17 years building a world-leading peptide platform, now employing over 600 staff including a 130-plus-member senior R&D team across a 7,000-square-meter R&D center and two manufacturing bases. Its API manufacturing site has twice passed on-site US FDA audits, and the company offers more than 20 peptide APIs — including semaglutide, tirzepatide, leuprolide acetate, bivalirudin, goserelin acetate, and oxytocin — with over 10 products carrying completed US DMF filings, alongside cosmetic peptides such as acetyl hexapeptide-8 and copper peptide. With peptide API capacity exceeding 10 tons annually and formulation capacity above 30 million vials, JYMed provides end-to-end CRO, CMO, and CDMO services from custom synthesis through commercial-scale production, serving markets across North America, Europe, Asia, the Middle East, and Africa.
No hay comentarios disponibles.
Deja tu valoración & comentario